as 12-18-2024 2:44pm EST
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Founded: | N/A | Country: | United States |
Employees: | 13 | City: | EMERYVILLE |
Market Cap: | N/A | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | N/A |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | N/A | EPS Growth: | N/A |
52 Week Low/High: | N/A | Next Earning Date: | N/A |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
XOMAO Breaking Stock News: Dive into XOMAO Ticker-Specific Updates for Smart Investing
MT Newswires
16 days ago
GlobeNewswire
16 days ago
Zacks
a month ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
Zacks
a month ago
Associated Press Finance
a month ago
GlobeNewswire
a month ago
The information presented on this page, "XOMAO AGNC Investment Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.